DRAINHUNT Trademark

Trademark Overview


On Friday, September 30, 2016, a trademark application was filed for DRAINHUNT with the United States Patent and Trademark Office. The USPTO has given the DRAINHUNT trademark a serial number of 79205165. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, August 16, 2024. This trademark is owned by Immungenetics AG. The DRAINHUNT trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:

Biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for use in neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for use in trinucleotide repeat disorders, in particular for use in Huntington's Chorea; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for preventing neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for preventing trinucleotide repeat disorders, in particular for preventing Huntington's Chorea; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient ...

Chemical products for the production of viral, retroviral and non-viral vectors
drainhunt

General Information


Serial Number79205165
Word MarkDRAINHUNT
Filing DateFriday, September 30, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, August 16, 2024
Registration Number5388879
Registration DateTuesday, January 30, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2017

Trademark Statements


Goods and ServicesBiochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for use in neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for use in trinucleotide repeat disorders, in particular for use in Huntington's Chorea; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for preventing neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for preventing trinucleotide repeat disorders, in particular for preventing Huntington's Chorea; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for the treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for the treatment of trinucleotide repeat disorders, in particular for the treatment of Huntington'a chorea; biochemical and chemical preparations for medical purposes in oral administration forms, namely, pills, tablets, dragées, capsules, liquids, drops, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes in oral administration forms, namely, pills, tablets, dragées, capsules, liquids, drops, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of trinucleotide repeat disorders; biochemical and chemical preparations for medical purposes in oral administration forms, namely, pills, tablets, dragées, capsules, liquids, drops, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of Huntington's Chorea; biochemical and chemical preparations for medical purposes in parenteral administration forms, namely, injection solutions and infusion solutions, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes in parenteral administration forms, namely, injection solutions and infusion solutions, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of trinucleotide repeat disorders; biochemical and chemical preparations for medical purposes in parenteral administration forms, namely, injection solutions and infusion solutions, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of Huntington's chorea
Pseudo MarkDRAIN HUNT
Goods and ServicesChemical products for the production of viral, retroviral and non-viral vectors

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, August 16, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, August 16, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImmungenetics AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Party NameImmungenetics AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Party NameImmungenetics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressDE

Trademark Events


Event DateEvent Description
Saturday, April 15, 2017NON-FINAL ACTION WRITTEN
Thursday, April 13, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Saturday, April 15, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 15, 2017ASSIGNED TO EXAMINER
Sunday, April 16, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, April 19, 2017APPLICATION FILING RECEIPT MAILED
Wednesday, April 19, 2017REFUSAL PROCESSED BY MPU
Wednesday, April 19, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 5, 2017REFUSAL PROCESSED BY IB
Tuesday, September 19, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 20, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 25, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 14, 2017PUBLISHED FOR OPPOSITION
Tuesday, November 14, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 30, 2018REGISTERED-PRINCIPAL REGISTER
Monday, April 30, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, May 2, 2018FINAL DISPOSITION PROCESSED
Tuesday, September 19, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, September 23, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, October 9, 2017ASSIGNED TO LIE
Monday, January 30, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, August 16, 2024CANCELLED SECTION 71
Friday, March 11, 2022CHANGE OF NAME/ADDRESS REC'D FROM IB
Wednesday, May 2, 2018FINAL DISPOSITION NOTICE SENT TO IB
Friday, June 8, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, November 12, 2021NEW REPRESENTATIVE AT IB RECEIVED
Friday, March 11, 2022NEW REPRESENTATIVE AT IB RECEIVED